Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

Abstract Safe and effective new oral therapies for autoimmune, allergic, and inflammatory conditions remain a significant therapeutic need. Here, we investigate the human pharmacokinetics, pharmacodynamics (PDs), and safety of the selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor, remibru...

Full description

Bibliographic Details
Main Authors: Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamaria Jakab, Magdalena Kistowska, Arvind Kinhikar, Alessio Maiolica, Angela Sinn, Rainard Fuhr, Bruno Cenni
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13005

Internet

https://doi.org/10.1111/cts.13005

Similar Items